ZARONTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zarontin, and when can generic versions of Zarontin launch?
Zarontin is a drug marketed by Parke Davis and Parke-davis and is included in two NDAs.
The generic ingredient in ZARONTIN is ethosuximide. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the ethosuximide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zarontin
A generic version of ZARONTIN was approved as ethosuximide by PHARM ASSOC on November 22nd, 2000.
Summary for ZARONTIN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Clinical Trials: | 5 |
| Patent Applications: | 4,030 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ZARONTIN |
| What excipients (inactive ingredients) are in ZARONTIN? | ZARONTIN excipients list |
| DailyMed Link: | ZARONTIN at DailyMed |
Recent Clinical Trials for ZARONTIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Zhejiang University | Early Phase 1 |
| Fondation Apicil | Phase 2 |
| University Hospital, Clermont-Ferrand | Phase 2 |
Pharmacology for ZARONTIN
| Drug Class | Anti-epileptic Agent |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Anatomical Therapeutic Chemical (ATC) Classes for ZARONTIN
US Patents and Regulatory Information for ZARONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | ZARONTIN | ethosuximide | CAPSULE;ORAL | 012380-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Parke-davis | ZARONTIN | ethosuximide | SYRUP;ORAL | 080258-001 | Approved Prior to Jan 1, 1982 | AA | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
